Leqembi (lecanemab)
Additional monitoring
- Region
- 🇪🇺 EU
- Active substance
- lecanemab
- Company
- Eisai GmbH
- Status
- Authorised
- Therapeutic area
- Cognitive Dysfunction; Alzheimer Disease
- CHMP opinion
- Thu 14 Nov 2024
- EU approval
- Tue 15 Apr 2025
- Designations
- Additional monitoring
- Application
- EMEA/H/C/005966
- ATC
- N06DX04
- Official record
- www.ema.europa.eu
Indication
Leqembi is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer’s disease (Early Alzheimer’s disease) who are apolipoprotein E 4 (ApoE ε4) non-carriers or heterozygotes with confirmed amyloid pathology (see section 4.4).
Regulatory milestones
No milestones recorded in the last year.
Follow Leqembi
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.